GlassScriptPhysician profile
Carmen Kosicek
NPI 1255863767
$538,787.23
in general payments reported to CMS, 2019-2025
28 companies · $4,931 in 2025
The $4,931 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $214K · 2022: $258K · 2023: $57K · 2024: $4,554 · 2025: $4,931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $12K · Consulting Fee: $11K · Travel and Lodging: $8,298 · Gift: $1,414 · Education: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,448.50 |
| Food and Beverage | $12,363.97 |
| Consulting Fee | $11,315.00 |
| Travel and Lodging | $8,298.23 |
| Gift | $1,413.84 |
| Education | $361.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $206,912.78 | 2021-2025 | Austedo Xr, Austedo, Uzedy |
| Abbvie INC. | $201,560.85 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60,502.22 | 2021-2025 | Caplyta |
| Uswm, LLC | $34,836.21 | 2021-2023 | Zimhi, Lucemyra |
| Allergan, INC. | $8,996.16 | 2021 | |
| Biogen, INC. | $7,143.25 | 2022-2025 | Zurzuvae |
| Corium, LLC | $5,789.70 | 2021-2025 | Azstarys |
| Alkermes, INC. | $3,840.42 | 2021-2025 | Aristada, Vivitrol, Aristada Initio |
| E.R. Squibb & Sons, L.L.C. | $2,192.53 | 2024-2025 | Cobenfy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,100.00 | 2021 | |
| Axsome Therapeutics, INC. | $1,343.08 | 2023-2025 | Auvelity |
| Tris Pharma INC | $666.84 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Janssen Pharmaceuticals, INC | $570.03 | 2024-2025 | Spravato, Invega, Invega Sustenna |
| Eisai INC. | $552.13 | 2021 | |
| Sunovion Pharmaceuticals INC. | $442.11 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $405.20 | 2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $192.57 | 2021-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $135.06 | 2021-2024 | Ingrezza |
| Sage Therapeutics, LLC | $109.08 | 2024 | |
| Idorsia Pharmaceuticals US INC | $107.24 | 2023-2024 | Quviviq |
| Indivior INC. | $90.99 | 2024-2025 | Sublocade |
| Avion Pharmaceuticals | $54.05 | 2021 | |
| Avanir Pharmaceuticals, INC. | $53.58 | 2021-2022 | |
| Lundbeck LLC | $48.61 | 2024 | Rexulti |
| Orexo US, INC. | $45.90 | 2021 | |
| Almatica Pharma LLC | $43.50 | 2022 | |
| Noven Therapeutics, LLC | $35.51 | 2024 | Xelstrym, Secuado |
| Cosette Pharmaceuticals INC. | $17.63 | 2025 | Vyleesi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Kosicek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.